Wim Wuyts

13.6k total citations · 1 hit paper
199 papers, 5.3k citations indexed

About

Wim Wuyts is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Pathology and Forensic Medicine. According to data from OpenAlex, Wim Wuyts has authored 199 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 170 papers in Pulmonary and Respiratory Medicine, 57 papers in Physiology and 27 papers in Pathology and Forensic Medicine. Recurrent topics in Wim Wuyts's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (151 papers), Sarcoidosis and Beryllium Toxicity Research (43 papers) and Systemic Sclerosis and Related Diseases (25 papers). Wim Wuyts is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (151 papers), Sarcoidosis and Beryllium Toxicity Research (43 papers) and Systemic Sclerosis and Related Diseases (25 papers). Wim Wuyts collaborates with scholars based in Belgium, United States and Germany. Wim Wuyts's co-authors include Geert M. Verleden, Bart Vanaudenaerde, Athol U. Wells, Lieven Dupont, Toby M. Maher, Dirk Van Raemdonck, Vincent Cottin, Eric Verbeken, Michael Kreuter and Maurits Demedts and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Wim Wuyts

190 papers receiving 5.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases

2018 386 citations Vincent Cottin, Wim Wuyts et al. profile →

Peers

Countries citing papers authored by Wim Wuyts

Since Specialization

Citations

This map shows the geographic impact of Wim Wuyts's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wim Wuyts with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wim Wuyts more than expected).

Fields of papers citing papers by Wim Wuyts

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wim Wuyts. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wim Wuyts. The network helps show where Wim Wuyts may publish in the future.

Co-authorship network of co-authors of Wim Wuyts

This figure shows the co-authorship network connecting the top 25 collaborators of Wim Wuyts. A scholar is included among the top collaborators of Wim Wuyts based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wim Wuyts. Wim Wuyts is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Effect of Admilparant, a Lysophosphatidic Acid Receptor 1 Antagonist, on Disease Progression in Pulmonary Fibrosis 2025 ·CHEST Journal ·(unknown), Toby M. Maher, Wim Wuyts, Claudia Valenzuela, Michael R. Hamblin, Sinae Kim, (unknown), (unknown), Luca Richeldi	1
2	The Role of Inflammation and Fibrosis in Interstitial Lung Disease Treatment Decisions 2024 ·American Journal of Respiratory and Critical Care Medicine ·Jürgen Behr, Margaret L. Salisbury, Simon Walsh, Anna J. Podolanczuk, Lida P. Hariri, Gary M. Hunninghake, Martin Kolb, Christopher J. Ryerson, Vincent Cottin, Mary Beth Beasley, Tamera J. Corte, Allan R. Glanville, Ayodeji Adegunsoye, Cory M. Hogaboam, Wim Wuyts, Imre Noth, Justin M. Oldham, Luca Richeldi, Ganesh Raghu, Athol U. Wells	11
3	Study protocol of an international patient-led registry in patients with pulmonary fibrosis using online home monitoring: I-FILE 2023 ·BMC Pulmonary Medicine ·(unknown), Catharina C. Moor, Κατερίνα Αντωνίου, Vincent Cottin, Anna‐Maria Hoffmann‐Vold, (unknown), Michael Kreuter, Philip L. Molyneaux, Wim Wuyts, Marlies Wijsenbeek	5
4	Autoantibodies against the NineTeen complex and U5 RNP in systemic sclerosis 2023 ·Journal of Autoimmunity ·Jean‐Baptiste Vulsteke, Vanessa Smith, Carolien Bonroy, Jan Lenaerts, Rita Derua, Wim Wuyts, Daniël Blockmans, Petra De Haes, Yves Piette, Ellen De Langhe, Xavier Bossuyt	1
5	Clinical course of suspected familial and sporadic idiopathic pulmonary fibrosis: Data from the PROOF‐Next registry 2023 ·Respirology ·Antoine Froidure, Benjamin Bondue, Caroline Dahlqvist, Julien Guiot, (unknown), (unknown), Guy Brusselle, (unknown), Hans Slabbynck, Wim Wuyts	3
6	Detection of anti-eIF2B autoantibodies in systemic sclerosis by immunoprecipitation-mass spectrometry 2023 ·Lara D. Veeken ·Jean‐Baptiste Vulsteke, Frédéric Coutant, David Gonçalves, Benoît Nespola, Petra De Haes, Wim Wuyts, Daniël Blockmans, Ellen De Langhe, Nicole Fabien, Xavier Bossuyt	5
7	Efficacy and Safety of Pirfenidone in Advanced Versus Non-Advanced Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Six Clinical Studies 2023 ·Advances in Therapy ·Jürgen Behr, Steven D. Nathan, Ulrich Costabel, Carlo Albera, Wim Wuyts, Marilyn K. Glassberg, (unknown), Giuseppe Alvaro, Frank Gilberg, Katerina Samara, Lisa Lancaster	6
8	Intrafamilial Correlation and Variability in the Clinical Evolution of Pulmonary Fibrosis 2023 ·CHEST Journal ·(unknown), Adriana Dubbeldam, (unknown), (unknown), Laurens De Sadeleer, (unknown), Ellen De Langhe, Jonas Yserbyt, Birgit Weynand, Marianne Carlon, Johny Verschakelen, Sascha Vermeer, Stijn E. Verleden, Wim Wuyts	1
9	Ultrasonographic Presentation and Anatomic Distribution of Lung Involvement in Patients with Rheumatoid Arthritis 2023 ·Diagnostics ·(unknown), Alexandros Kalkanis, (unknown), Heleen Cypers, (unknown), Barbara Neerinckx, V. Taelman, Patrick Verschueren, Wim Wuyts	6
10	ERS International Congress 2022: highlights from the Interstitial Lung Diseases Assembly 2023 ·ERJ Open Research ·Τheodoros Karampitsakos, (unknown), Daan W. Loth, Iftikhar Nadeem, (unknown), Marlies Wijsenbeek, Wim Wuyts, Elena Bargagli, Antoine Froidure, Paolo Spagnolo, Marcel Veltkamp, María Molina‐Molina, Cormac McCarthy, Katerina Antoniou, Michael Kreuter, Catharina C. Moor	2
11	MUC5B rs35705950 minor allele associates with older age and better survival in idiopathic pulmonary fibrosis 2022 ·Respirology ·Joanne J. van der Vis, Antje Prasse, Elisabetta Renzoni, Carmel Stock, (unknown), Toby M. Maher, Francesco Bonella, Raphaël Borie, Bruno Crestani, Martin Petřek, Wim Wuyts, (unknown), Philip L. Molyneaux, Jan C. Grutters, Coline H.M. van Moorsel	9
12	Radiologic and Histologic Correlates of Early Interstitial Lung Changes in Explanted Lungs 2022 ·Radiology ·Stijn E. Verleden, Arno Vanstapel, Joseph Jacob, (unknown), Jeroen Hendriks, Laurens J. Ceulemans, Dirk Van Raemdonck, Laurens De Sadeleer, Robin Vos, Johanna M. Kwakkel‐van Erp, Arne Neyrinck, Geert M. Verleden, Matthieu Boone, Wim Janssens, Els Wauters, Birgit Weynand, Danny Jonigk, Johny Verschakelen, Wim Wuyts	11
13	Defining and predicting progression in non-IPF interstitial lung disease 2021 ·Respiratory Medicine ·(unknown), Laurens De Sadeleer, Jonas Yserbyt, Ellen De Langhe, Adriana Dubbeldam, Erik Verbeken, Geert M. Verleden, (unknown), Johny Verschakelen, Robin Vos, Birgit Weynand, Stijn E. Verleden, Wim Wuyts	4
14	Economic Burden and Management of Systemic Sclerosis-Associated Interstitial Lung Disease in 8 European Countries: The BUILDup Delphi Consensus Study 2020 ·Advances in Therapy ·Jesper Rømhild Davidsen, Jelle Miedema, Wim Wuyts, Maritta Kilpeläinen, Spyridon Papiris, Effrosyni D. Manali, Carlos Robalo Cordeiro, António Morais, (unknown), Guus Asijee, (unknown), (unknown)	10
15	The Burden of Progressive Fibrosing Interstitial Lung Disease: A DELPHI Approach 2020 ·Advances in Therapy ·Wim Wuyts, Spyridon Papiris, Effrosyni D. Manali, Maritta Kilpeläinen, Jesper Rømhild Davidsen, Jelle Miedema, Carlos Robalo Cordeiro, António Morais, Maite Artés, Guus Asijee, (unknown), (unknown)	19
16	Towards the Essence of Progressiveness: Bringing Progressive Fibrosing Interstitial Lung Disease (PF-ILD) to the Next Stage 2020 ·Journal of Clinical Medicine ·Laurens De Sadeleer, (unknown), Jonas Yserbyt, Wim Wuyts	14
17	Granulomatous lung disease in two workers making light bulbs 2019 ·American Journal of Industrial Medicine ·(unknown), Eric Verbeken, (unknown), (unknown), Jonas Yserbyt, Wim Wuyts, Rudy Swennen, Peter Hoet, Benoît Nemery	11
18	Sildenafil increases stroke volume during exercise in patients with chronic thromboembolic pulmonary hypertension 2014 ·European Heart Journal ·Guido Claessen, André La Gerche, Jean‐Yves Wielandts, Wim Wuyts, Jan Bogaert, Piet Claus, Marion Delcroix, Hein Heidbüchel	1
19	The Role of the IL23/IL17 Axis in Bronchiolitis Obliterans Syndrome After Lung Transplantation 2008 ·American Journal of Transplantation ·Bart Vanaudenaerde, Stéphanie I. De Vleeschauwer, Robin Vos, Isabelle Meyts, Dominique Bullens, Veerle Reynders, Wim Wuyts, Dirk Van Raemdonck, Lieven Dupont, Geert M. Verleden	143
20	Mechanisms of Interleukin 1 β -Induced Human Airway Smooth Muscle Hyporesponsiveness to Histamine 2001 ·American Journal of Respiratory and Critical Care Medicine ·Jan Pype, (unknown), (unknown), Lieven Dupont, Wim Wuyts, Jcw Mak, Peter J. Barnes, M. Demedts, Geert M. Verleden	37

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact